Evidence map›Paper›PMID 28508995›Full record

ReviewNeurochemical research2017

L-Carnitine and Acetyl-L-carnitine Roles and Neuroprotection in Developing Brain.

Gustavo C Ferreira, Mary C McKenna

Abstract readReview
In one paragraph

Review in Neurochemical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 1 pooled it
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 1 synthesis or guideline pooled it, 308 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 2 countries.

Gustavo C FerreiraInstitute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Mary C McKennaDepartment of Pediatrics, University of Maryland School of Medicine, 655 W. Baltimore Street, BRB 13-019, Baltimore, MD, 21201, USA. mmckenna@umaryland.edu.
University of Maryland, Baltimore · US

Funding

SPECTRIN-DEPENDENT MEMBRANE DOMAINS IN THE DEVELOPING CNSP01HD016596 · NICHD · UNIVERSITY OF MARYLAND BALTIMORE · PI MCKENNA, MARY C · 1985 to 2013
$12.8M
Project IV- Cerebellar Function After Hypoxia-Ischemia and Precipitating InflammationP01HD085928 · NICHD · UNIVERSITY OF MARYLAND BALTIMORE · PI BEARER, CYNTHIA FRANCES, MCCARTHY, MARGARET M. · 2016 to 2020
$6.3M
NICHD NIH HHS P01 HD016596NICHD NIH HHS P01 HD085928
6 · The paper itself

Abstract

L-Carnitine functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. Treatment with L-carnitine can ameliorate metabolic imbalances in many inborn errors of metabolism. In recent years there has been considerable interest in the therapeutic potential of L-carnitine and its acetylated derivative acetyl-L-carnitine (ALCAR) for neuroprotection in a number of disorders including hypoxia-ischemia, traumatic brain injury, Alzheimer's disease and in conditions leading to central or peripheral nervous system injury. There is compelling evidence from preclinical studies that L-carnitine and ALCAR can improve energy status, decrease oxidative stress and prevent subsequent cell death in models of adult, neonatal and pediatric brain injury. ALCAR can provide an acetyl moiety that can be oxidized for energy, used as a precursor for acetylcholine, or incorporated into glutamate, glutamine and GABA, or into lipids for myelination and cell growth. Administration of ALCAR after brain injury in rat pups improved long-term functional outcomes, including memory. Additional studies are needed to better explore the potential of L-carnitine and ALCAR for protection of developing brain as there is an urgent need for therapies that can improve outcome after neonatal and pediatric brain injury.

Indexed as

AcetylcarnitineAnimalsBrainBrain InjuriesCarnitineHumansNeuroprotectionOxidative StressAcetylcarnitineCarnitineAcetyl-L-carnitineCarnitine shuttleInborn errors of metabolismL-CarnitineMetabolismNeonatal hypoxia-ischemiaNeuroprotectionPediatric traumatic brain injury

Identifiers

PMID28508995
PMCPMC5621476
OpenAlexW2615540589

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.